[go: up one dir, main page]

WO1997034637A3 - Therapie photodynamique dans laquelle des recepteurs d'hormones nucleaires sont utilises pour cibler des photosensibilisateurs - Google Patents

Therapie photodynamique dans laquelle des recepteurs d'hormones nucleaires sont utilises pour cibler des photosensibilisateurs Download PDF

Info

Publication number
WO1997034637A3
WO1997034637A3 PCT/US1997/004542 US9704542W WO9734637A3 WO 1997034637 A3 WO1997034637 A3 WO 1997034637A3 US 9704542 W US9704542 W US 9704542W WO 9734637 A3 WO9734637 A3 WO 9734637A3
Authority
WO
WIPO (PCT)
Prior art keywords
hormone
receptors
photodynamic therapy
nuclear hormone
hormone receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/004542
Other languages
English (en)
Other versions
WO1997034637A2 (fr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to AU25387/97A priority Critical patent/AU2538797A/en
Publication of WO1997034637A2 publication Critical patent/WO1997034637A2/fr
Publication of WO1997034637A3 publication Critical patent/WO1997034637A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un mécanisme nouveau pour localiser les photosensibilisateurs, à savoir l'interaction avec les récepteurs de haute affinité qui régulent les signaux hormonaux transmis par les stéroïdes (et quelques autres hormones telles que la thyroxine, les rétinoïdes, et des éléments de la famille de la vitamine D). Ces récepteurs ne s'expriment que dans des types spécifiques de cellules, et confèrent par leur expression une sensibilité aux hormones auxdites cellules. La présente invention concerne des conjugués hormone/chromofore dotés d'une affinité de liaison raisonnable pour la protéine réceptrice de l'hormone, ainsi que des procédés permettant d'administrer aux patients lesdits conjugués comme agents photosensibilisateurs spécifiques capables, au moment de l'irradiation par de la lumière visible, de diriger les atteintes létales vers des lignées de cellules contenant le récepteur. Lesdits conjugués hormone/chromofore liés aux récepteurs d'hormones nucléaires peuvent être utilisés comme systèmes sélectifs d'administration de molécules dans la thérapie photodynamique.
PCT/US1997/004542 1996-03-22 1997-03-21 Therapie photodynamique dans laquelle des recepteurs d'hormones nucleaires sont utilises pour cibler des photosensibilisateurs Ceased WO1997034637A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU25387/97A AU2538797A (en) 1996-03-22 1997-03-21 Photodynamic therapy using nuclear hormone receptors to target photosensitizers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1387196P 1996-03-22 1996-03-22
US60/013,871 1996-03-22

Publications (2)

Publication Number Publication Date
WO1997034637A2 WO1997034637A2 (fr) 1997-09-25
WO1997034637A3 true WO1997034637A3 (fr) 1998-01-29

Family

ID=21762233

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/004542 Ceased WO1997034637A2 (fr) 1996-03-22 1997-03-21 Therapie photodynamique dans laquelle des recepteurs d'hormones nucleaires sont utilises pour cibler des photosensibilisateurs

Country Status (2)

Country Link
AU (1) AU2538797A (fr)
WO (1) WO1997034637A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074673A1 (fr) * 1999-06-03 2000-12-14 The General Hospital Corporation Traitement et analyse de troubles proliferatifs
WO2005120588A2 (fr) * 2004-05-26 2005-12-22 The Curators Of The University Of Missouri Peptides delivres a des noyaux cellulaires
CN108524919A (zh) 2012-05-17 2018-09-14 延伸生物科学股份有限公司 用于改进的药物递送的载体
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
CA2964463C (fr) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Conjugues de vitamine d therapeutiques
CN120225181A (zh) 2022-09-30 2025-06-27 延伸生物科学股份有限公司 长效甲状旁腺激素

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014493A1 (fr) * 1991-02-20 1992-09-03 Christopher Capelli Elements conjugues non proteiques de liaison de recepteur intracellulaire
WO1995010307A1 (fr) * 1993-10-12 1995-04-20 Board Of Regents, The University Of Texas System Sensibilisation aux rayonnements utilisant des texaphyrines
US5591422A (en) * 1995-06-02 1997-01-07 Pharmacyclics, Inc. Texaphyrin complexes having improved functionalization

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014493A1 (fr) * 1991-02-20 1992-09-03 Christopher Capelli Elements conjugues non proteiques de liaison de recepteur intracellulaire
WO1995010307A1 (fr) * 1993-10-12 1995-04-20 Board Of Regents, The University Of Texas System Sensibilisation aux rayonnements utilisant des texaphyrines
US5591422A (en) * 1995-06-02 1997-01-07 Pharmacyclics, Inc. Texaphyrin complexes having improved functionalization

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BATS, JAN W. ET AL: "Synthesis of oxochlorins from the red blood pigment heme and their transformation into potentially biologically active chlorin derivatives", LIEBIGS ANN. (1995), (9), 1617-31 CODEN: LANAEM;ISSN: 0947-3440, 1995, XP002047327 *
MONTFORTS, FRANZ PETER ET AL: "Tailored chlorins for photodynamic tumor therapy and as model systems for photosynthesis", ANGEW. CHEM. (1992), 104(12), 1650-2 (SEE ALSO ANGEW. CHEM., INT. ED. ENGL., 1992, 31(12), 1592-4) CODEN: ANCEAD;ISSN: 0044-8249, 1992, XP002047328 *
T.V. AKHLYNINA ET AL.: "Insulin-mediated intracellular targeting enhances the photodynamic activity of Chlorin e6.", CANCER RESEARCH, vol. 55, 1 March 1995 (1995-03-01), MD US, pages 1014 - 1019, XP002047329 *

Also Published As

Publication number Publication date
WO1997034637A2 (fr) 1997-09-25
AU2538797A (en) 1997-10-10

Similar Documents

Publication Publication Date Title
Carpenter et al. 125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts.
Allison et al. The effects of plasma lipoproteins on in vitro tumor cell killing and in vivo tumor photosensitization with benzoporphyrin derivative
NO941155L (no) Nye konjugater for innföring av nukleinsyre i höyere eukariotiske celler
DE69226197D1 (de) Hämoglobine als arzneimittelabgabesystem
ES2153367T3 (es) Derivados de clorofila y de bacterioclorofila, su preparacion y composiciones farmaceuticas que los contienen.
AU6268894A (en) Compositions for oral delivery of active agents
ES2010745A6 (es) Procedimiento para la obtencion de un sistema terapeutico para la aplicacion combinada transdermal de estrogenos y de gestagenos.
Moscicki et al. Reduction of the Fraction of Circulating Helper-Induced T Cells Identified by Monoclonal Antibodies in Psoriatic Patients Treated with Long-term Psoralen/Ultraviolet-A Radiation (PUVA)
EA199800946A1 (ru) Концентрированный препарат антител
Rahimipour et al. Receptor-mediated targeting of a photosensitizer by its conjugation to gonadotropin-releasing hormone analogues
WO1992019213A3 (fr) Amelioration de l'absorption, par les tissus anormaux, d'anticorps, d'agents specifiques a certaines tumeurs ou de conjugues de ces derniers pour l'imagerie a des fins de diagnostic ou la therapie
WO1997034637A3 (fr) Therapie photodynamique dans laquelle des recepteurs d'hormones nucleaires sont utilises pour cibler des photosensibilisateurs
AU8366398A (en) Trifunctional reagent for conjugation to a biomolecule
WO1997028822A1 (fr) Composition et procede permettant de causer des dommages photodynamiques a des cellules cibles
Bellisario et al. Human chorionic gonadotropin. V. Tissue specificity of binding and partial characterization of soluble human chorionic gonadotropin-receptor complexes.
WO1998009647A3 (fr) Compositions de cyanidine et leurs usages therapeutiques et diagnostiques
TW261615B (fr)
Mercado-Simmen et al. Relaxin receptors in the myometrium and cervix of the pig
WO2002003850A2 (fr) Marquage photoselectif de cibles biologiques
Humphrey et al. Anti-fertility effects of an analog of luteinizing hormone releasing hormone (LHRH) in rats
WO2000001820A3 (fr) Molecules d'acide nucleique codant pour les co-activateurs des recepteurs d'hormones nucleaires
Jiang et al. Enhanced photodynamic killing of target cells by either monoclonal antibody or low density lipoprotein mediated delivery systems
AU7299591A (en) Delivery of agents
Ma et al. Receptor-mediated endocytosis of antigens overcomes the requirement for HLA-DM in class II-restricted antigen presentation.
Lev-Goldman et al. Synthesis and active oxygen generation by new emodin derivatives and their gonadotropin-releasing hormone conjugates

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD GH

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97533718

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase